Clinical Trials

4 enrolled

Prostatic Neoplasms

NCT03300505 2025-05-13

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

9 enrolled 14 charts

Prostatic Neoplasms

NCT05075577 2025-02-28

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1/2 Terminated

77 enrolled

Prostatic Neoplasms

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

49 enrolled 33 charts

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 Terminated

74 enrolled

Prostatic Neoplasms, Patient Preference

NCT04033328 2023-12-15

Study of ORIC-101 in Combination With Enzalutamide

41 enrolled

Prostatic Neoplasms

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

3 enrolled 9 charts

Prostatic Neoplasms

NCT02640534 2023-06-27

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

169 enrolled

Prostatic Neoplasms

NCT02438007 2023-03-15

ARMOR3-SV

Phase 3 Terminated

953 enrolled

Prostatic Neoplasms

NCT03531827 2022-07-12

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

4 enrolled 12 charts

Prostatic Neoplasms

NCT02508636 2021-10-12

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

11 enrolled 17 charts

Prostatic Neoplasms

NCT03478904 2021-05-10

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

1 enrolled 8 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02685267 2021-04-09

Doce/Enza

9 enrolled 11 charts

Prostatic Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

1 enrolled 7 charts

Prostatic Neoplasms

NCT02500901 2019-10-21

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

2 enrolled 8 charts

Prostatic Neoplasms

NCT02491411 2018-07-12

DEXTER

Phase NA Terminated

5 enrolled 5 charts

Prostatic Neoplasms

NCT02441517 2018-04-19

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Phase 4 Terminated

4 enrolled 12 charts